Document Detail


Phase I trial of photodynamic therapy in the treatment of recurrent superficial transitional cell carcinoma of the bladder.
MedLine Citation:
PMID:  9255289     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: A Phase I trial of photodynamic therapy (PDT) in the treatment of superficial transitional cell carcinoma (TCC) of the bladder was performed. METHODS: Twenty patients with recurrent superficial TCC of the bladder after receiving a mean of 2.6 (range 1 to 6) courses of intravesical therapy were treated with PDT. The photosensitizer Photofrin II dose was 1.5 or 2.0 mg/kg. A 630-nm intravesical red laser was used to activate the photosensitizer 2 days after administration of Photofrin II. A 0.01% intralipid solution was used as a bladder-filling medium to scatter light and achieve more homogeneous light distribution. Light doses from 5.1 to 25.6 J/cm2 (total dosage 1500 to 5032 J) were used to illuminate the bladder. RESULTS: Twenty patients underwent 21 treatments with PDT. Complications included asymptomatic reflux in 4 patients. One other patient, treated at the highest total light dose, experienced bladder contraction and fibrosis. Nine patients (45%) had no tumor evident at cystoscopy, on random biopsies, or in urinary cytology at the 3-month evaluation after treatment. Four patients remained without recurrent disease for 23 to 56 months. Sixteen of 20 (80%) patients experienced recurrence, and 8 of the 16 underwent cystectomy. CONCLUSIONS: An intravenous photosensitizer dose of 1.5 mg/kg Photofrin II followed by light energy in the range of 13 J/cm2 (total light dose 2500 to 3250 J) was defined as a safe treatment parameter and resulted in tumor responses. With present technologies, administration of PDT requires careful dosimetry.
Authors:
M M Walther; T F Delaney; P D Smith; W S Friauf; G F Thomas; T H Shawker; M P Vargas; P L Choyke; W M Linehan; E H Abraham; P G Okunieff; E Glatstein
Related Documents :
6446839 - The effects of intravesical instillation of thio-tepa on the recurrence rate of bladder...
3006439 - Radical irradiation of t2 and t3 bladder carcinoma. a retrospective investigation.
8426399 - The use of nuclear morphometry in predicting recurrence of transitional cell carcinoma.
8136939 - Intravesical rtnf therapy of superficial bladder cancer. a phase i study of recombinant...
3656529 - The outcome of conservative treatment of carcinoma in situ of the bladder.
9258089 - Late urological complications and malignancies after curative radiotherapy for gynecolo...
3177809 - Sequelae of thrombotic or hemorrhagic complications following l-asparaginase therapy fo...
9890109 - Prevention and treatment of adverse effects of corticosteroids in systemic lupus erythe...
11857289 - Irinotecan hydrochloride for the treatment of recurrent and refractory non-hodgkin lymp...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase I; Journal Article    
Journal Detail:
Title:  Urology     Volume:  50     ISSN:  0090-4295     ISO Abbreviation:  Urology     Publication Date:  1997 Aug 
Date Detail:
Created Date:  1997-09-08     Completed Date:  1997-09-08     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0366151     Medline TA:  Urology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  199-206     Citation Subset:  IM    
Affiliation:
Urologic Oncology Branch, National Center for Research Resources, Bethesda, Maryland, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Carcinoma, Transitional Cell / drug therapy*
Female
Follow-Up Studies
Humans
Male
Middle Aged
Neoplasm Recurrence, Local / drug therapy*
Photochemotherapy* / adverse effects,  instrumentation
Urinary Bladder Neoplasms / drug therapy*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Retroperitoneoscopic renal biopsy in extremely obese patients.
Next Document:  Twenty-year experience with jejunal conduits.